𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Prevalence of BRCA1 and BRCA2 germline mutations in young breast cancer patients: A population-based study

✍ Scribed by Silvia de Sanjosé; Mélanie Léoné; Victoria Bérez; Angel Izquierdo; Rebeca Font; Joan M. Brunet; Thierry Louat; Loreto Vilardell; Joan Borras; Pau Viladiu; F. Xavier Bosch; Gilbert M. Lenoir; Olga M. Sinilnikova


Publisher
John Wiley and Sons
Year
2003
Tongue
French
Weight
82 KB
Volume
106
Category
Article
ISSN
0020-7136

No coin nor oath required. For personal study only.

✦ Synopsis


Abstract

Our aim was to estimate the prevalence of mutations in the BRCA1 and BRCA2 genes among unselected incident cases of breast cancer in young women. We identified 158 incident breast cancer cases diagnosed before age 46 years in predefined geographic areas in Girona and Tarragona, Spain, during 1995–1997. Of these, 136 (86%) provided information on family history of cancer and were screened for BRCA1 and BRCA2 mutations. Nine of the 136 (6.6%) were found to carry BRCA deleterious mutations (MUT) (1 BRCA1 and 8 BRCA2), and 20 were detected with rare BRCA variants of unknown significance (UV). Both MUT and US BRCA alterations were more frequent in younger patients: 7 (11.6%) MUT and 12 (19.3%) UV carriers were found in the group of 62 patients younger than 40 years, whereas 2 (2.7%) MUT and 9 (12%) US carriers were identified in the group of 74 patients aged 40–45. Family history of breast and ovarian cancers suggestive of hereditary condition (at least 2 first‐ or second‐degree relatives affected with breast cancer or at least 1 relative affected with ovarian cancer or early‐onset breast cancer) was absent for 5 of 9 MUT carriers. This suggests that BRCA screening policies based on family history of cancer would miss a considerable proportion of BRCA mutations. Mutations in the BRCA1 and BRCA2 genes explain at least 10% of breast cancer cases diagnosed before age 40 years. The contribution of these genes to early‐onset breast cancer is likely to be even higher given that certain UV cases might be disease‐associated. © 2003 Wiley‐Liss, Inc.


📜 SIMILAR VOLUMES


BRCA1 and BRCA2 germline mutations in Ko
✍ Jae Hong Seo; Dae-Yeon Cho; Se-Hyun Ahn; Kyung-Sik Yoon; Chang-Soo Kang; Hyun Mi 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 93 KB 👁 2 views

In order to evaluate the role of BRCA1 and BRCA2 germline mutations in Korean patients with sporadic breast cancer, 97 patients with sporadic breast cancer were analyzed for mutations in the BRCA1 and BRCA2 coding regions, by using a combination of fluorescent-conformation sensitive gel electrophore

Prevalence of BRCA1 and BRCA2 mutations
✍ Muhammad U. Rashid; Anbreen Zaidi; Diana Torres; Faisal Sultan; Axel Benner; Bil 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 French ⚖ 312 KB 👁 2 views

## Abstract Among Asian countries, Pakistan has the highest rates of breast and ovarian cancer. To assess the contribution of the __BRCA1__ and __BRCA2__ germ line mutations to these high rates, we conducted the first study of 176 Pakistani breast and ovarian cancer patients, selected on family his

Germline mutations in the BRCA1 and BRCA
✍ A. Esra Manguoǧlu; Güven Lüleci; Tayfun Özçelik; Taner Çolak; Hagit Schayek; Mus 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 47 KB 👁 2 views

In this study we genotyped Turkish breast/ovarian cancer patients for BRCA1/BRCA2 mutations: protein truncation test (PTT) for exon 11 BRCA1 of and, multiplex PCR and denaturing gradient gel electrophoresis (DGGE) for BRCA2, complemented by DNA sequencing. In addition, a modified restriction assay w